Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.
Zinzani PL, Izutsu K, Mehta-Shah N, Barta SK, Ishitsuka K, Córdoba R, Kusumoto S, Bachy E, Cwynarski K, Gritti G, Prica A, Jacobsen E, Feldman T, Guillermin Y, Ennishi D, Yoon DH, Domenech ED, Zain J, Wang J, Kim JS, Poel MV, Jin J, Wu S, Chen Y, Moriyama T, Inoue A, Nakajima K, Horwitz SM.
Zinzani PL, et al. Among authors: moriyama t.
Lancet Oncol. 2024 Oct 29:S1470-2045(24)00503-5. doi: 10.1016/S1470-2045(24)00503-5. Online ahead of print.
Lancet Oncol. 2024.
PMID: 39486433